Replies to post #33995 on Ariad Pharmaceuticals Inc fka ARIA

[lax20m]

When I read your post my initial reaction was to scream FALSE but after looking through press releases you are correct. They did say during one of their 2nd quarter press releases that they would start a pivotal 113 trial by the end of Q3. With that being said, is it reasonable to think they are in a good position to do so? This question is likely above most people's pay grade on this board (certainly above mine) but I'd be interested to hear educated opinions. Is it reasonable to think they gleaned enough info from the short duration of the current P2 portion of the current P1/P2 113 trial to design a well thought out pivotal trial? What am I missing here. This is a new trial correct, not the same one that is currently ongoing.